Adisan Biotechnologies Private Limited

Adisan Biotechnologies Private Limited - pharma in Pune, Maharashtra, India. FY 2026 financials & compliance.
CIN U24239PN2012PTC144248 Incorporated 01 August 2012 ROC Pune HQ Pune, Maharashtra, India
Active Private Limited Company pharma
Revenue · FY 2022
₹32,286
▼ 99% YoY
Net loss · FY 2022
₹4.92 Lakh
Latest filing
EBITDA · FY 2022
-₹16,446
EBITDA margin -50.9%
Authorised capital
₹15 Lakh
Registered with MCA
Paid-up capital
₹15 Lakh
Issued & subscribed
Satisfied charges
₹2.2 Cr
No open charges
Company age
14 yrs
Est. 2012
Directors on board
2
As per MCA filings

About Adisan Biotechnologies Private Limited

Data last updated:

Adisan Biotechnologies Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 August 2012 and has been in existence for over 14 years.

The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24239PN2012PTC144248. Its GSTIN is 27AAKCA7999M1ZL (Maharashtra).

The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹15 Lakh. It is led by directors Aditya Ramesh Devadhar and Suvarnarekha Aditya Devadhar.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No 19 S. No. 297/1&3 298/1 To 5 3031/3 & 304/1 To 3 Mouze Ambervet Tal. Mulshi, Pune, Maharashtra, India – 412115.

As per the financials filed for FY 2022, the company reported a revenue of ₹32,286, a decline of 99% compared to the previous year. For the same year it recorded a net loss of ₹4.92 Lakh and EBITDA of -₹16,446 (EBITDA margin -50.9%). Revenue has declined at a compounded annual rate (CAGR) of 68% over three years and 60% over five years.

As per MCA filings, the company has satisfied charges of ₹2.2 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website adisanlabs.com.

Company details

CIN U24239PN2012PTC144248
Registration Number 144248
Incorporation Date 01 August 2012
ROC Pune
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant

Contact details

Adisan Biotechnologies Private Limited's registered office is in Pune, Maharashtra. Its website is adisanlabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Plot No 19 S. No. 297/1&3 298/1 To 5 3031/3 & 304/1 To 3 Mouze Ambervet Tal. Mulshi, Pune, Maharashtra, India – 412115
  • Industry
    Pharma, Drug Formulation & Development, Animal Pharmaceuticals & Healthcare

To see the full contact details of Adisan Biotechnologies Private Limited, buy the company report.

Comprehensive company report
Adisan Biotechnologies Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Financials of Adisan Biotechnologies Private Limited

FY 2025 filings available

Adisan Biotechnologies Private Limited reported revenue of ₹32,286 (down 99% YoY) for FY 2022.

Revenue · FY 2022
₹32,286 ▼ 99%
Net loss · FY 2022
₹4.92 Lakh
EBITDA · FY 2022
-₹16,446 margin -50.9%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 99%
3 years · compounded
▼ 68%
5 years · compounded
▼ 60%

Revenue has declined at a compounded annual rate (CAGR) of 60% over five years, including a 99% fall in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19FY 2017-18
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹32,286
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA-₹16,446
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹4.92 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19FY 2017-18
Profitability
EBITDA Margin-50.9%
Net Profit Margin
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Adisan Biotechnologies Private Limited, buy the company report.

Board of directors of Adisan Biotechnologies Private Limited

Adisan Biotechnologies has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Aditya Ramesh DevadharDirector01 Aug 201214 Years 3 MonthsCurrent
Suvarnarekha Aditya DevadharDirector30 Dec 201411 Years 10 MonthsCurrent

Auditor

Adisan Biotechnologies Private Limited is audited by PRANJAL JOSHI & CO for the financial year 2021.

Auditor firmFinancial yearFirm registration number
PRANJAL JOSHI & COFY 2021131584W

Shareholding

The shareholding of Adisan Biotechnologies Private Limited is on record for 4 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2021FY 2020FY 2017FY 2016
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Adisan Biotechnologies Private Limited, buy the company report.

Charges & borrowings

Open charges
None
Satisfied charges
₹2.2 Cr
Breakdown by lending institutions
The Federal Bank Ltd₹2.20 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
08 Jan 201610617409The Federal Bank Ltd₹94 LakhSatisfied
08 Jan 201610617411The Federal Bank Ltd₹1.26 CrSatisfied

To see the full charge records of Adisan Biotechnologies Private Limited, buy the company report.

Total charge records: 2 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Adisan Biotechnologies Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Adisan Biotechnologies has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AAKCA7999M1ZLMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Adisan Biotechnologies Private Limited, buy the company report.

Recent activity

Adisan Biotechnologies Private Limited has 8 board changes on record since 2012: 2 appointments and 6 cessations. The latest: Shailendra Raman Bhamare ceased to be Director on 04 Mar 2017.

AGM
Adisan Biotechnologies Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Adisan Biotechnologies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune.
Charges
A charge registered on 08 Jan 2016 via Charge ID 10617409 with The Federal Bank Ltd was fully satisfied on 14 Mar 2017.
Charges
A charge registered on 08 Jan 2016 via Charge ID 10617411 with The Federal Bank Ltd was fully satisfied on 14 Mar 2017.
Ceased
Shailendra Raman Bhamare ceased to be Director.
Ceased
Tanvi Vivek Londhe ceased to be Director.
Ceased
Vishal Somnath Saraf ceased to be Director.
Charges
A charge with The Federal Bank Ltd amounted to Rs. 94.00 Lakh with Charge ID 10617409 was registered on 08 Jan 2016.
Charges
A charge with The Federal Bank Ltd amounted to Rs. 126.00 Lakh with Charge ID 10617411 was registered on 08 Jan 2016.
Ceased
Suvarnarekha Aditya Devadhar ceased to be Additional Director.
Ceased
Dhananjay Yeshwant Paranjape ceased to be Director.
Appointed
Suvarnarekha Aditya Devadhar was appointed as Director.

3 earlier events are in the company report.

Frequently asked questions

Adisan Biotechnologies is an active private limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 August 2012 (14+ years old) and is registered under CIN U24239PN2012PTC144248.

Adisan Biotechnologies has 2 current directors:

The latest financial statements of Adisan Biotechnologies on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Adisan Biotechnologies is 27AAKCA7999M1ZL, registered in Maharashtra.

The CIN (Corporate Identification Number) of Adisan Biotechnologies is U24239PN2012PTC144248. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Adisan Biotechnologies was incorporated on 01 August 2012, making it 14+ years old. It is registered with the Registrar of Companies, Pune.

Shailendra Raman Bhamare ceased to be Director on 04 Mar 2017. Tanvi Vivek Londhe ceased to be Director on 04 Mar 2017. Vishal Somnath Saraf ceased to be Director on 04 Mar 2017. Adisan Biotechnologies has 8 board changes on record in total.

Adisan Biotechnologies can be reached through the website adisanlabs.com. Its registered office is in Pune, Maharashtra, India.

The registered office of Adisan Biotechnologies is at Plot No 19 S. No. 2971&3 2981 To 5 30313 & 3041 To 3 Mouze Ambervet Tal. Mulshi, Pune, Maharashtra, India – 412115.

Adisan Biotechnologies operates in the pharma industry, in the drug formulation and development segment.